Value Investor
Start free

Mangoceuticals

MGRX on Nasdaq. Market value $9m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

What to watch out for

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 18 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

  • Jacob D. Cohen
    Insider or founder
    at least 21.5%+6.9 pts
    (filed with 1 related holder)
    Since 9 March 2026
  • Greenfield Investments, Ltd
    Passive investor
    at least 14.4%
    (filed with 1 related holder)
    Since 13 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 2 sold $173,700.

  • JOHNSTON EUGENE M
    CFO
    Sold
    Date
    15 December 2025
    Shares
    3,333
    Price
    $1.17
    Value
    $3,900
  • JOHNSTON EUGENE M
    CFO
    Sold
    Date
    9 December 2025
    Shares
    5,000
    Price
    $1.20
    Value
    $6,000
  • JOHNSTON EUGENE M
    CFO
    Sold
    Date
    5 December 2025
    Shares
    10,000
    Price
    $1.13
    Value
    $11,300
  • Hamilton Alex P.
    Director
    Sold
    Date
    19 November 2025
    Shares
    125,000
    Price
    $1.22
    Value
    $152,500

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Mangoceuticals’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 1 Apr 2026, plus the 10-Q filed 13 Aug 2026 and 5 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “These factors raise substantial doubt about the ability of the Company to continue as a going concern.”
    Show the full paragraph
    These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the next twelve months. As reflected in the accompanying condensed consolidated financial statements, the Company had a net loss of $ 1,312,931 and $ 4,716,072 for the three and six months ended June 30, 2026, respectively, and an accumulated deficit of $ 45,363,283 as of June 30, 2026. The Company will need to raise additional capital to successfully execute its business plan of which there can be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the 12 months from the date of issuance of this filing. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

    From the 10-Q filed 13 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.